TEVA Q1 2022 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$37B

Q1 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$3.7B-8.1% YoY

Gross Profit

$1.7B47.5% margin

Operating Income

-$713M-19.5% margin

Net Income

-$955M-26.1% margin

EPS (Diluted)

$-0.86

QoQ Revenue Growth

-10.7%

Cash Flow

Operating Cash Flow

-$49M

Free Cash Flow

-$206M

Stock-Based Comp.

$24M

Balance Sheet

Total Assets

$47.1B

Total Liabilities

$36.8B

Stockholders' Equity

$9.3B

Cash & Equivalents

$2.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.7B	$4.0B	-8.1%
Gross Profit	$1.7B	$1.9B	-7.3%
Operating Income	-$713M	$434M	-264.3%
Net Income	-$955M	$77M	-1340.3%

Revenue Segments

Product

$3.1B86%

Distribution Service

$358M10%

Product and Service, Other

$129M4%

License

$38M1%

Geographic Segments

North America Segment

$1.7B51%

Europe Segment

$1.2B34%

International Markets

$492M15%